These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34233947)

  • 1. The Molecular Biology of Phosphodiesterase 4 Enzymes as Pharmacological Targets: An Interplay of Isoforms, Conformational States, and Inhibitors.
    Paes D; Schepers M; Rombaut B; van den Hove D; Vanmierlo T; Prickaerts J
    Pharmacol Rev; 2021 Jul; 73(3):1016-1049. PubMed ID: 34233947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDE4 as a target for cognition enhancement.
    Richter W; Menniti FS; Zhang HT; Conti M
    Expert Opin Ther Targets; 2013 Sep; 17(9):1011-27. PubMed ID: 23883342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDE4 inhibitors for disease therapy: advances and future perspective.
    Du B; Luo M; Ren C; Zhang J
    Future Med Chem; 2023 Jul; 15(13):1185-1207. PubMed ID: 37470147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting phosphodiesterase 4 as a therapeutic strategy for cognitive improvement.
    Wei X; Yu G; Shen H; Luo Y; Shang T; Shen R; Xi M; Sun H
    Bioorg Chem; 2023 Jan; 130():106278. PubMed ID: 36413930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders.
    Bhat A; Ray B; Mahalakshmi AM; Tuladhar S; Nandakumar DN; Srinivasan M; Essa MM; Chidambaram SB; Guillemin GJ; Sakharkar MK
    Pharmacol Res; 2020 Oct; 160():105078. PubMed ID: 32673703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4).
    Cameron RT; Coleman RG; Day JP; Yalla KC; Houslay MD; Adams DR; Shoichet BK; Baillie GS
    Biochem Pharmacol; 2013 May; 85(9):1297-305. PubMed ID: 23473803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK.
    Li X; Vadrevu S; Dunlop A; Day J; Advant N; Troeger J; Klussmann E; Jaffrey E; Hay RT; Adams DR; Houslay MD; Baillie GS
    Biochem J; 2010 Apr; 428(1):55-65. PubMed ID: 20196770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders.
    Wu C; Rajagopalan S
    Obes Rev; 2016 May; 17(5):429-41. PubMed ID: 26997580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase 4 and its inhibitors in inflammatory diseases.
    Jin SL; Ding SL; Lin SC
    Chang Gung Med J; 2012; 35(3):197-210. PubMed ID: 22735051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases.
    Souness JE; Rao S
    Cell Signal; 1997; 9(3-4):227-36. PubMed ID: 9218122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase-4 Inhibition in Parkinson's Disease: Molecular Insights and Therapeutic Potential.
    Roy D; Balasubramanian S; Krishnamurthy PT; Sola P; Rymbai E
    Cell Mol Neurobiol; 2023 Aug; 43(6):2713-2741. PubMed ID: 37074485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PAN-selective inhibition of cAMP-phosphodiesterase 4 (PDE4) induces gastroparesis in mice.
    McDonough W; Aragon IV; Rich J; Murphy JM; Abou Saleh L; Boyd A; Koloteva A; Richter W
    FASEB J; 2020 Sep; 34(9):12533-12548. PubMed ID: 32738081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DC591017, a phosphodiesterase-4 (PDE4) inhibitor with robust anti-inflammation through regulating PKA-CREB signaling.
    Li H; Li J; Zhang X; Feng C; Fan C; Yang X; Zhang R; Zhu F; Zhou Y; Xu Y; Liu H; Tang W
    Biochem Pharmacol; 2020 Jul; 177():113958. PubMed ID: 32251674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PDE4 cAMP-Specific Phosphodiesterases: Targets for Drugs with Antidepressant and Memory-Enhancing Action.
    Bolger GB
    Adv Neurobiol; 2017; 17():63-102. PubMed ID: 28956330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational investigation of the dynamic control of cAMP signaling by PDE4 isoform types.
    Paes D; Hermans S; van den Hove D; Vanmierlo T; Prickaerts J; Carlier A
    Biophys J; 2022 Jul; 121(14):2693-2711. PubMed ID: 35717559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs.
    Zhang HT
    Curr Pharm Des; 2009; 15(14):1688-98. PubMed ID: 19442182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the development of phosphodiesterase-4 inhibitors.
    Li G; He D; Cai X; Guan W; Zhang Y; Wu JQ; Yao H
    Eur J Med Chem; 2023 Mar; 250():115195. PubMed ID: 36809706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases.
    Omar F; Findlay JE; Carfray G; Allcock RW; Jiang Z; Moore C; Muir AL; Lannoy M; Fertig BA; Mai D; Day JP; Bolger G; Baillie GS; Schwiebert E; Klussmann E; Pyne NJ; Ong ACM; Bowers K; Adam JM; Adams DR; Houslay MD; Henderson DJP
    Proc Natl Acad Sci U S A; 2019 Jul; 116(27):13320-13329. PubMed ID: 31209056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF.
    Pullamsetti SS; Banat GA; Schmall A; Szibor M; Pomagruk D; Hänze J; Kolosionek E; Wilhelm J; Braun T; Grimminger F; Seeger W; Schermuly RT; Savai R
    Oncogene; 2013 Feb; 32(9):1121-34. PubMed ID: 22525277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDE4 associates with different scaffolding proteins: modulating interactions as treatment for certain diseases.
    McCahill AC; Huston E; Li X; Houslay MD
    Handb Exp Pharmacol; 2008; (186):125-66. PubMed ID: 18491051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.